RenovoRx, Inc. financial data

Symbol
RNXT on Nasdaq
Industry
Pharmaceutical Preparations
Location
2570 W. El Camino Real, Ste. 320,, Mountain View, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Apr 1, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 54.7 % -94.5%
Return On Equity -156 % +94.5%
Return On Assets -101 % +60.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.5M shares +117%
Common Stock, Shares, Outstanding 24M shares +125%
Entity Public Float 26.6M USD +71.6%
Common Stock, Value, Issued 2K USD +100%
Weighted Average Number of Shares Outstanding, Basic 22.3M shares +116%
Weighted Average Number of Shares Outstanding, Diluted 22.3M shares +116%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.03M USD +6.32%
General and Administrative Expense 4.89M USD -20.1%
Operating Income (Loss) -11M USD +3.74%
Nonoperating Income (Expense) 2.16M USD +85.2%
Net Income (Loss) Attributable to Parent -8.81M USD +13.9%
Earnings Per Share, Basic -0.4 USD/shares +59.6%
Earnings Per Share, Diluted -0.4 USD/shares +59.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.15M USD +510%
Accounts Receivable, after Allowance for Credit Loss, Current 43K USD
Other Assets, Current 303K USD +1163%
Assets, Current 7.83M USD +434%
Property, Plant and Equipment, Net 12K USD
Operating Lease, Right-of-Use Asset 278K USD
Assets 8.12M USD +454%
Accounts Payable, Current 586K USD +4.46%
Accrued Liabilities, Current 1.32M USD +115%
Liabilities, Current 1.91M USD +62.5%
Operating Lease, Liability, Noncurrent 212K USD
Liabilities 3.64M USD -18.5%
Retained Earnings (Accumulated Deficit) -50.2M USD -21.3%
Stockholders' Equity Attributable to Parent 4.48M USD
Liabilities and Equity 8.12M USD +454%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.2M USD +18.6%
Net Cash Provided by (Used in) Financing Activities 5.42M USD
Net Cash Provided by (Used in) Investing Activities 2.03M USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 24M shares +125%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.22M USD
Deferred Tax Assets, Valuation Allowance 16.8M USD +31.7%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure
Deferred Tax Assets, Gross 16.9M USD +32.3%
Operating Lease, Liability 278K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -2.39M USD -2.66%
Lessee, Operating Lease, Liability, to be Paid 315K USD
Operating Lease, Liability, Current 66K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 118K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 86K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 37K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 111K USD
Deferred Tax Assets, Operating Loss Carryforwards 11M USD +24.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares 0%
Unrecognized Tax Benefits 827K USD +28%
Additional Paid in Capital 54.4M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 79K USD
Share-based Payment Arrangement, Expense 239K USD +67.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%